Citeline logo with a tagline underneath that reads a Norstella company.
Contact Us
Report
February 10, 2026

In Vivo Outlook 2026 Financing eBook

The life sciences industry enters 2026 with cautious confidence. After two years of volatility, the sector has found its footing in an environment that rewards disciplined growth, sharper portfolio decisions and capital efficiency.

This report from In Vivo brings together data, insights and perspectives that provide clarity for innovators, dealmakers, pharma strategists and investors.

Why Download
  • See where biopharma funding is really flowing in 2026
  • Benchmark your strategy against industry leaders and active deal‑makers
  • Understand how financing connects to M&A, innovation, and long‑term growth

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

サイトラインより、関連する製品・サービス・コンテンツに関する情報をお届けする場合があります。配信停止や受信内容の管理をご希望の場合は、プリファレンスセンターをご利用ください。

ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。


FAQ

After a period of volatility, the biopharma industry enters 2026 with cautious optimism. Companies are preparing for a major patent cliff by shifting toward disciplined growth, driven by tighter capital efficiency, more selective investment, and renewed momentum in mergers and acquisitions (M&A).
Between 2025 and 2030, biopharma products generating roughly $300 billion in annual revenues are expected to lose exclusivity. This creates significant pressure on large pharma portfolios, pushing affected companies toward M&A, licensing, and innovation-driven strategies to replace at-risk revenues while also transforming competitive dynamics across the industry.
Investor sentiment has improved, equity valuations are more favorable, and public companies are raising capital more successfully through follow-on offerings, private investments in public equity (PIPEs), and debt. However, clinical-stage companies are attracting the most investor interest, while early-stage start-ups continue to face tighter access to capital.